42 min
Red Journal Podcast November 1, 2022: Radiotherapy for Breast Cancer in Combination With Novel Systemic Therapies ASTRO Journals
-
- Science
Dr. Jeffrey Olsen, Associate Professor of Radiation Oncology at the University of Colorado and section editor of our gastrointestinal section, co-leads a discussion along with our Editor-in-Chief Editor-in-Chief Dr. Sue Yom hosts Dr. Sara Alcorn, Associate Editor and Associate Professor of Radiation Oncology at the University of Minnesota, who first-authored this month’s Oncology Scan, Toxicity and Timing of Breast Radiotherapy with Overlapping Systemic Therapies and Dr. Jennifer Bellon, Section Editor for breast cancers. Director of Breast Radiation Oncology at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and first author of a Red Journal paper from May 2022 called Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer, as well as Dr. Jeffrey Cao, Provincial Breast Tumour Team Lead for Alberta Health Services and Clinical Associate Professor at the University of Calgary, who supervised a new article in this month’s issue, Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study.
Dr. Jeffrey Olsen, Associate Professor of Radiation Oncology at the University of Colorado and section editor of our gastrointestinal section, co-leads a discussion along with our Editor-in-Chief Editor-in-Chief Dr. Sue Yom hosts Dr. Sara Alcorn, Associate Editor and Associate Professor of Radiation Oncology at the University of Minnesota, who first-authored this month’s Oncology Scan, Toxicity and Timing of Breast Radiotherapy with Overlapping Systemic Therapies and Dr. Jennifer Bellon, Section Editor for breast cancers. Director of Breast Radiation Oncology at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and first author of a Red Journal paper from May 2022 called Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer, as well as Dr. Jeffrey Cao, Provincial Breast Tumour Team Lead for Alberta Health Services and Clinical Associate Professor at the University of Calgary, who supervised a new article in this month’s issue, Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study.
42 min